Vtv Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Vtv Therapeutics Inc 's ROA in the second quarter of 2026?
Vtv Therapeutics Inc recorded a cumulative net loss of $-6 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -6.82%.

However, within the Healthcare sector 271 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 2656, from total ROA ranking in the first quarter of 2026 at 4596.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	231.92 %	209.42 %	135.7 %	131.28 %	-42.97 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-6	-1	-31	-28	-24
Return On Assets (TTM)	-6.82 %	-0.93 %	-50.19 %	-57.94 %	-68.47 %
VTVT's Total Ranking	# 2656	# 4596	# 4107	# 4260	# 4238
Total Assets (TTM) in million	88	99	90	99	26
Seq. Total Assets Change	-11.35 %	9.92 %	-9.62 %	276.92 %	-17.36 %
Seq. Net Income Change	-	-	-	-	-

VTVT's 5 Years Annual ROA >> Back to VTVT Management Effectiveness >> Compare VTVT ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 94
Sector	# 272
Overall	# 3039

Return On Assets Statistics
High	Average	Low
-0.93 %	-115.63 %	-288.34 %
(Mar 31 2026)		(Mar 31 2020)

Financial Statements
Vtv Therapeutics Inc 's Assets	$ 88 million	VTVT's Balance sheet
Vtv Therapeutics Inc 's Income	$ -13 million	Quarterly VTVT's Income Statement
VTVT's Income by Division		See VTVT's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	135.7 %	254.01 %	-68.21 %	33.03 %	72.25 %
Total Assets in million	90	38	11	34	25
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-31	-23	-26	-25	-18
Annual Return On Assets	-34.57 %	-59.53 %	-241.01 %	-73.99 %	-69.6 %

VTVT's 5 Years Annual ROA >> Back to VTVT Management Effectiveness >> Compare VTVT ROA to its Competitors

More Return On Assets Ratios
VTVT's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
VTVT's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for VTVT's Competitors
Subscribers only: Roa for Vtv Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for VTVT's Customers

You may also want to know
VTVT's Roi	VTVT's Inventory Turnover Ratio	VTVT's Growth Rates	VTVT's Dividend Comparisons
	VTVT's Profitability Ratios	VTVT's Asset Turnover Ratio	VTVT's Dividend Growth
VTVT's Roe	VTVT's Valuation Ratios	VTVT's Financial Strength Ratios	VTVT's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:22:59+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.